A risk for returned travellers: the “post-antibiotic era”

Geethanie A T P Fernando, Peter J Collignon and Jan M Bell
Med J Aust 2010; 193 (1): . || doi: 10.5694/j.1326-5377.2010.tb03747.x
Published online: 5 July 2010

To the Editor: Infections caused by multiresistant gram-negative organisms are difficult to treat. Carbapenems are often used as a last resort but even these are under threat with the emergence of acquired metallo-b-lactamases worldwide, including Australia,1,2 India, China and Europe.

  • 1 Infectious Diseases and Microbiology Unit, Canberra Hospital, Canberra, ACT.
  • 2 SA Pathology (Women’s and Children’s Hospital), Adelaide, SA.

  • 1. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 2007; 20: 440-458.
  • 2. Peleg AYC, Franklin C, Bell JM, Spelman DW. Dissemination of the metallo-β-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005; 41: 1549-1556.
  • 3. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53: 5046-5054.
  • 4. Health Protection Agency. National resistance alert: carbapanemases in Enterobacteriaceae. UK: Health Protection Report 2009; 3(4): 3-4. (accessed May 2010).


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.